Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyâs lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naĂŻve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointâs kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Source
No articles found.
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
SmileDirectClub was founded on one simple belief: everyone deserves a smile they l...
SmileDirectClub was founded on one simple belie...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing...
scPharmaceuticals is a clinical-stage pharmaceu...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
Join the National Investor Network and get the latest information with your interests in mind.